FrancophonIA/ELRC3.0 huggingface dataset:
English: Pelmeg 6 mg solution for injection in pre-filled syringe
Slovenian: IME ZDRAVILA Pelmeg 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SYRINGE LABEL
Slovenian: PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
English: NAME OF THE MEDICINAL PRODUCT Pelmeg 6 mg solution for injection pegfilgrastim NAME OF THE MARKETING AUTHORISATION HOLDER Mundipharma EXPIRY DATE
Slovenian: IME ZDRAVILA Pelmeg 6 mg raztopina za injiciranje pegfilgrastim
English: Skin and subcutaneous tissue disorders
Slovenian: Bolezni mišičnoskeletnega sistema in vezivnega tkiva bolečina v kosteh mišično-skeletna bolečina
English: This medicinal product contains 30 mg sorbitol in each pre-filed syringe which is equivalent to 50 mg / mL.
Slovenian: Zdravilo Pelmeg vsebuje sorbitol (E 420) in natrijev acetat To zdravilo vsebuje 30 mg sorbitola v eni napolnjeni injekcijski brizgi, kar je enako 50 mg/ml.
English: The safety and efficacy of Pelmeg have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g., nitrosoureas.
Slovenian: Pri bolnikih, ki dobivajo kemoterapijo, povezano z odloženo mielosupresijo, na primer nitrozouree,
English: Bone pain Musculoskeletal pain (myalgia, arthralgia, pain in extremity, back pain, musculoskeletal pain, neck pain)
Slovenian: mišično-skeletna bolečina, bolečina v vratu)
English: • pain at the site of injection.
Slovenian: Splošne težave in spremembe na mestu aplikacije bolečina na mestu injiciranja,
English: PharmaKorell GmbH Marie-Curie-Str. 8 79539 Loerrach Germany
Slovenian: PharmaKorell GmbH Marie-Curie-Str. 8
English: 6.6 Special precautions for disposal and other handling Before administration, Pelmeg solution should be inspected visually for particulate matter.
Slovenian: Pred uporabo morate raztopino zdravila Pelmeg pregledati glede vidnih delcev.
English: Used syring barrel
Slovenian: Uporabljeni valj brizge
English: Three reported cases show a causal relationship between the adverse drug reaction (ADR) StevensJohnson syndrome and pegfilgrastim.
Slovenian: Trije poročani primeri kažejo na vzročno povezanost med neželenim učinkom zdravila (NUZ)
English: • damage to the tiny filters inside your kidneys (glomerulonephritis).
Slovenian:  kožni vaskulitis (vnetje krvnih žil v koži)  okvara drobnih filtrov v ledvicah (glomerulonefritis)  pordelost na mestu injiciranja  izkašljevanje krvi (hemoptiza)
English: Acute
Slovenian: Bat
English: How to store Pelmeg
Slovenian: Shranjevanje zdravila Pelmeg
English: Pulmonary adverse events
Slovenian: Neželene reakcije na pljučih
English: Strength Pharmaceutical Form
Slovenian: ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija) velikost pakiranja
English: Route of Administration
Slovenian: številka EU
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evotaz on 13 July 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Evotaz, veljavno po vsej Evropski uniji, izdala 13. julija 2015.
English: What measures are being taken to ensure the safe and effective use of Evotaz?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Evotaz?
English: Other information about Evotaz
Slovenian: Druge informacije o zdravilu Evotaz
English: This was comparable to a reduction in 87% of patients (304 of 348) treated with atazanavir and ritonavir.
Slovenian: To je bilo primerljivo z zmanjšanjem pri 87 % bolnikov (304 od 348), zdravljenih z atazanavirjem in ritonavirjem.
English: The main measure of effectiveness was the proportion of patients in whom the HIV-1 count in the blood (known as viral load) was reduced to less than 50 copies/ml after 48 weeks of treatment.
Slovenian: Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih se je število virusov HIV-1 v krvi (kar se imenuje virusno breme) po 48 tednih zdravljenja zmanjšalo na manj kot 50 kopij/ml.
English: This is a summary of the European public assessment report (EPAR) for Evotaz.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Evotaz.
English: The full EPAR and risk management plan summary for Evotaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Evotaz sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Evotaz must not be taken by patients who have moderately or severely reduced liver function.
Slovenian: Zdravila Evotaz ne smejo jemati bolniki, ki imajo zmerno ali hudo poslabšano delovanje jeter.
English: A risk management plan has been developed to ensure that Evotaz is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Evotaz je bil pripravljen načrt obvladovanja tveganj.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Evotaz's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Evotaz večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: It must also not be taken by patients taking certain medicines because of the possibility of interactions which could be harmful.
Slovenian: Prav tako ga ne smejo jemati bolniki, ki uporabljajo nekatera druga zdravila, saj lahko ta medsebojno delujejo, kar je škodljivo.
English: It is not intended to provide practical advice on how to use Evotaz.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What benefits of Evotaz have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Evotaz izkazalo v študijah?
English: In addition, the use of atazanavir with cobicistat has been evaluated in one main study in 698 HIV patients who had not been treated previously.
Slovenian: Poleg tega so uporabo atazanavirja v kombinaciji s kobicistatom ocenili v eni glavni študiji pri 698 bolnikih, okuženih s HIV, ki se še niso zdravili.
English: The medicine is for use only in patients whose infection is not expected to be resistant to atazanavir.
Slovenian: Zdravilo je namenjeno samo bolnikom, pri katerih okužba zelo verjetno ne bo odporna proti atazanavirju.
English: What is Evotaz and what is it used for?
Slovenian: Kaj je zdravilo Evotaz in za kaj se uporablja?
English: Evotaz is an antiviral medicine used in combination with other medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Evotaz je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
English: What are the risks associated with Evotaz?
Slovenian: Kakšna tveganja so povezana z zdravilom Evotaz?
English: This therefore boosts atazanavir's antiviral effect.
Slovenian: To okrepi protivirusni učinek atazanavirja.
English: Evotaz atazanavir / cobicistat
Slovenian: Evotaz atazanavir/kobicistat
English: Evotaz is available as tablets that contain 300 mg of atazanavir and 150 mg of cobicistat.
Slovenian: Zdravilo Evotaz je na voljo v obliki tablet, ki vsebujejo 300 mg atazanavirja in 150 mg kobicistata.
English: Cobicistat increases the level of atazanavir in the blood by slowing its breakdown.
Slovenian: Kobicistat poviša raven atazanavirja v krvi, tako da upočasni njegov razkroj.
English: Overall, 85% of patients (293 out of 344) treated with atazanavir and cobicistat achieved this reduction.
Slovenian: To zmanjšanje je doseglo 85 % bolnikov (293 od 344), zdravljenih z atazanavirjem in kobicistatom.
English: The most common side effects with Evotaz (which may affect more than 1 in 10 people) are jaundice, which may show as yellow discoloration of the eye, and nausea (feeling sick).
Slovenian: Najpogostejša neželena učinka zdravila Evotaz (ki lahko prizadeneta več kot 1 osebo od 10) sta zlatenica, ki se lahko kaže kot porumenelost beločnice, in navzeja (slabost).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Evotaz, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: When the enzyme is blocked, the virus cannot reproduce itself and its spread in the body slows down.
Slovenian: Pri zaviranju tega encima se virus ne more razmnoževati, njegovo širjenje po telesu pa se upočasni.
English: For more information about treatment with Evotaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Evotaz preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Atazanavir is a protease inhibitor.
Slovenian: Atazanavir je zaviralec proteaze.
English: Why is Evotaz approved?
Slovenian: Zakaj je bilo zdravilo Evotaz odobreno?
English: Combining atazanavir and cobicistat in a single tablet has the potential of simplifying the dosing regimen.
Slovenian: Kombinacija atazanavirja in kobicistata v eni tableti lahko poenostavi režim odmerjanja.
English: Atazanavir and cobicistat were compared with atazanavir and ritonavir; all patients also received the HIV medicines emtricitabine and tenofovir disoproxil.
Slovenian: Atazanavir in kobicistat so primerjali z atazanavirjem in ritonavirjem; vsi bolniki so prejemali tudi zdravili proti virusu HIV, emtricitabin ter tenofovirdizoproksil.
English: The virus needs protease to make more viruses.
Slovenian: Virus potrebuje proteazo za svoje razmnoževanje.
English: For practical information about using Evotaz, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Evotaz naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: It does not cure HIV infection, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Slovenian: Zdravilo Evotaz ne ozdravi okužbe z virusom HIV ali aidsa, vendar lahko upočasni slabšanje imunskega sistema in prepreči razvoj okužb ter bolezni, povezanih z aidsom.
English: It blocks an HIV enzyme called protease from working.
Slovenian: Zavira delovanje encima virusa HIV, imenovanega proteaza.
English: Evotaz's adverse effects were similar to those that occur with the individual medicines.
Slovenian: Neželeni učinki zdravila Evotaz so bili podobni kot pri posameznih zdravilnih učinkovinah, ki ju vsebuje.
English: Because atazanavir and cobicistat have both previously been shown to be effective and are authorised for use in the treatment of HIV infection, studies were mainly carried out to show that Evotaz produced similar levels of atazanavir in the blood to the two active substances given separately, and to atazanavir given with a different booster medicine, ritonavir (an established combination).
Slovenian: Ker so dokazali, da sta atazanavir in kobicistat učinkovita in odobrena za uporabo pri zdravljenju okužbe HIV, so večino študij izvedli za dokazovanje, da je zdravilo Evotaz povzročilo podobne ravni atazanavirja v krvi kot obe zdravilni učinkovini, kadar sta se dajali ločeno, oziroma kot atazanavir v kombinaciji z drugim krepilnim zdravilom, ritonavirjem (uveljavljena kombinacija).
English: Evotaz can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection.
Slovenian: Zdravilo Evotaz se izdaja le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem okužb z virusom HIV.
English: Both active substances have already been shown to be effective and Evotaz may be a useful substitute for atazanavir accompanied by ritonavir as a booster.
Slovenian: Za obe zdravilni učinkovini so že dokazali, da sta učinkoviti, zato je lahko zdravilo Evotaz koristni nadomestek za atazanavir, ki se za krepitev učinka uporablja v kombinaciji z ritonavirjem.
English: The active substances in Evotaz are already available in the EU as individual medicines: atazanavir is available as Reyataz and cobicistat as Tybost.
Slovenian: Zdravilni učinkovini v zdravilu Evotaz sta že na voljo v EU kot samostojni zdravili: atazanavir je na voljo kot zdravilo Reyataz, kobicistat pa kot zdravilo Tybost.
English: Evotaz, taken with other HIV medicines, reduces HIV in the blood and keeps the virus at a low level.
Slovenian: Če se zdravilo Evotaz jemlje v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV, zmanjša količino tega virusa v krvi in ga ohranja na nizki ravni.
English: For the full list of all side effects reported with Evotaz, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Evotaz, glejte navodilo za uporabo.
English: How is Evotaz used?
Slovenian: Kako se zdravilo Evotaz uporablja?
English: Evotaz contains two active substances: atazanavir and cobicistat.
Slovenian: Zdravilo Evotaz vsebuje dve zdravilni učinkovini: atazanavir in kobicistat.
English: How does Evotaz work?
Slovenian: Kako zdravilo Evotaz deluje?
English: Evotaz contains the active substances atazanavir and cobicistat.
Slovenian: Zdravilo Evotaz vsebuje zdravilni učinkovini atazanavir in kobicistat.
English: Subcutaneous use vial (glass)
Slovenian: 150 mg prašek za raztopino za injiciranje subkutana uporaba viala (steklena)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled syringes (multipack)
Slovenian: 1 ml (150 mg/ml) 6 (3 x 2) napolnjenih injekcijskih peresnikov (skupno pakiranje)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled pens (multipack)
Slovenian: 1 ml (150 mg/ml) 6 (3 x 2) napolnjenih injekcijskih brizg (skupno pakiranje)
English: 1 ml (150 mg/ml) 2 pre-filled syringes
Slovenian: 1 ml (150 mg/ml) 2 napolnjena injekcijska peresnika
English: 1 ml (150 mg/ml) 1 pre-filled syringe
Slovenian: 1 ml (150 mg/ml) 1 napolnjena injekcijska brizga
English: 1 ml (150 mg/ml) 2 pre-filled pens
Slovenian: 1 ml (150 mg/ml) 2 napolnjeni injekcijski brizgi
English: This is a summary of the European public assessment report (EPAR) for Kovaltry.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Kovaltry.
English: What measures are being taken to ensure the safe and effective use of Kovaltry?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Kovaltry?
English: Other information about Kovaltry
Slovenian: Druge informacije o zdravilu Kovaltry
English: The full EPAR and risk management plan summary for Kovaltry can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Kovaltry sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Kovaltry octocog alfa
Slovenian: Kovaltry oktokog alfa
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Kovaltry večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: If they occur they may include: angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash over the whole body, headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (rapid heartbeat), tightness of the chest, tingling, vomiting and wheezing.
Slovenian: Če se pojavijo, lahko vključujejo angioedem (otekanje podkožnega tkiva), pekoč občutek in zbadanje na mestu injiciranja, mrzlico, rdečico, srbeč izpuščaj po vsem telesu, glavobol, koprivnico, hipotenzijo (nizek krvni tlak), letargijo, navzejo (slabost), nemir, tahikardijo (pospešen srčni utrip), tiščanje v prsnem košu, mravljinčenje, bruhanje in sopenje.
English: Data from a supportive study also confirmed the benefits of preventative treatment with Kovaltry in reducing the number of bleeds.
Slovenian: Tudi podatki podporne študije so potrdili koristi preventivnega zdravljenja z zdravilom Kovaltry pri zmanjševanju števila krvavitev.
English: A risk management plan has been developed to ensure that Kovaltry is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Kovaltry je bil pripravljen načrt obvladovanja tveganj.
English: It is not intended to provide practical advice on how to use Kovaltry.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Why is Kovaltry approved?
Slovenian: Zakaj je bilo zdravilo Kovaltry odobreno?
English: What are the risks associated with Kovaltry?
Slovenian: Kakšna tveganja so povezana z zdravilom Kovaltry?
English: The dose and frequency of the injections depend on whether Kovaltry is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Slovenian: Odmerek in pogostnost injiciranja sta odvisna od tega, ali se zdravilo Kovaltry uporablja za zdravljenje ali preprečevanje krvavitve, od resnosti bolnikovega pomanjkanja faktorja VIII, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
English: Kovaltry has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups.
Slovenian: Dokazali so, da je zdravilo Kovaltry učinkovito pri preprečevanju in zdravljenju krvavite, vključno z obvladovanjem izgube krvi med kirurškimi posegi, in se lahko uporablja pri vseh starostnih skupinah.
English: What is Kovaltry and what is it used for?
Slovenian: Kaj je zdravilo Kovaltry in za kaj se uporablja?
English: What benefits of Kovaltry have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Kovaltry izkazalo v študijah?
English: A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Kovaltry (mostly related to injuries).
Slovenian: Druga študija je vključevala 51 otrok, mlajših od 12 let, ki so se predhodno zdravili z drugimi zdravili s faktorjem VIII in so med zdravljenjem z zdravilom Kovaltry prav tako doživeli 3,8 krvavitve na leto (večinoma v povezavi s poškodbami).
English: The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII.
Slovenian: Zdravilna učinkovina zdravila Kovaltry, oktokog alfa, deluje v telesu enako kot humani faktor VIII.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kovaltry, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For the full list of all side effects and restrictions with Kovaltry, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Kovaltry glejte navodilo za uporabo.
English: Kovaltry can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Slovenian: Izdaja zdravila Kovaltry je le na recept, zdravljenje z njim pa mora biti pod nadzorom zdravnika z izkušnjami z zdravljenjem hemofilije.
English: Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Slovenian: Kovaltry je zdravilo, ki se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (prirojeno motnjo strjevanja krvi zaradi pomanjkanja koagulacijske beljakovine, imenovane faktor VIII).
English: The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Slovenian: Učinkovitost zdravila Kovaltry pri preprečevanju in zdravljenju krvavitev so dokazali v glavni študiji, ki je vključevala 62 bolnikov, starejših od 12 let, s hudo obliko hemofilije A, ki so se predhodno zdravili z drugimi zdravili s faktorjem VIII.
English: Kovaltry is available as a powder and solvent used to make a solution for injection.
Slovenian: Zdravilo Kovaltry je na voljo kot prašek in vehikel za pripravo raztopine za injiciranje.
English: In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.
Slovenian: Poleg tega bo podjetje, ki trži zdravilo Kovaltry, izvedlo študije, s katerimi bodo proučili varnost in učinkovitost zdravila pri bolnikih, ki se predhodno niso zdravili z drugimi zdravili s faktorjem VIII, in zagotovili dodatne dokaze o varnosti in učinkovitosti dolgotrajnega zdravljenja z zdravilom Kovaltry pri otrocih.
English: For more information about treatment with Kovaltry, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Kovaltry preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This compared with an average of 6.9 bleeds per year before Kovaltry treatment.
Slovenian: To povprečje je pred zdravljenjem z zdravilom Kovaltry znašalo 6,9 krvavitve na leto.
English: Hypersensitivity (allergic) reactions are uncommon with Kovaltry, affecting from 1 patient in 1,000 to less than 1 patient in 100.
Slovenian: Občasno so pri zdravilu Kovaltry opazili preobčutljivostne (alergijske) reakcije, ki prizadenejo med 1 osebo od 1 000 in manj kot 1 osebo od 100.
English: The number of bleeds that occurred during Kovaltry treatment was calculated as 3.8 bleeds per year on average (mostly into joints).
Slovenian: Število krvavitev med zdravljenjem z zdravilom Kovaltry so z izračunom pretvorili v povprečno 3,8 krvavitve na leto (večinoma v sklepe).
English: For practical information about using Kovaltry, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Kovaltry naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: About 70% of the bleeding events that occurred were managed with a single injection of Kovaltry, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases.
Slovenian: Približno 70 % krvavitev, ki so se pojavile, so obvladali z enkratno injekcijo zdravila Kovaltry, naslednjih 15 % pa se je odzvalo na drugo injekcijo.
English: How does Kovaltry work?
Slovenian: Kako zdravilo Kovaltry deluje?
English: How is Kovaltry used?
Slovenian: Kako se zdravilo Kovaltry uporablja?